Table 1

Baseline characteristics of the study subjects

Most sensitive (M>12, n=17)Intermediate sensitive (M=6.1–12, n=29)Least sensitive (M≤6, n=14)ANOVA p values
M (mg/kg/min)15.6±2.58.8±1.5*4.9±1.2*<0.0001
FH of T2D (%)35.317.226.60.279
Age (years)31.3±5.429.6±4.932.6±4.920.183
BMI (kg/m2)25.6±2.024.4±3.024.7±2.40.348
Waist (cm)84.4±6.180.3±9.182.6±8.560.543
SBP (mm Hg)127.3±8.7121.0±10.0127.6±14.20.085
DBP (mm Hg)74.9±8.872.8±19.277.8±12.10.190
HR (beats per minute)68.3±11.774.1±10.471.7±10.00.223
Hb (g/L)147±8150±9155±80.072
Cre (µmol/L)80.0±9.279.7±11.376.0±9.00.476
Albumin (g/L)40.6±6.042.6±2.444.3±3.0*0.037
Platelets (×109/L)223.3±38.1230.5±41.3267.5±54.50.018
ALT (U/L)24.8±8.519.7±9.234.3±24.3*0.009
AST (U/L)22.6±6.519.4±5.421.7±6.400.185
T chol (mmol/L)4.6±0.94.4±0.75.2±1.20.041
TG (mmol/L)0.9±0.40.9±0.51.2±0.50.051
HDL (mmol/L)1.2±0.21.2±0.31.2±0.30.692
LDL (mmol/L)3.0±0.82.8±0.63.4±1.00.072
FBG (mmol/L)4.9±0.44.6±0.44.8±0.30.071
Insulin (mIU/L)16.3±3.521.5±10.228.2±17.90.019
HbA1c (%)5.2±0.25.1±0.35.1±0.20.476
TSH (mIU/L)1.7±0.61.4±0.81.8±1.00.403
Fat mass (kg)18.3±4.719.6±6.018.1±6.80.293
Lean mass (kg)56.3±7.355.0±5.753.7±6.50.524
BMC (kg)3.0±0.63.2±1.22.8±0.50.420
Android (%fat)26.1±8.427.6±9.831.3±10.10.305
Gynoid (%fat)26.8±6.727.4±7.127.3±6.20.962
A:G ratio1.0±0.21.1±0.51.1±0.40.514
Total (%fat)24.5±5.725.7±6.126.6±5.90.605
TIMP-1 (ng/mL)75.8±16.880.2±23.385.0±16.10.483
PIIINP (µg/mL)8.6±1.98.1±1.18.5±0.60.433
HA (ng/mL)13.8±6.916.5±9.721.8±15.90.142
ELF score8.0±0.47.9±0.58.2±0.80.329
NAFLD score−3.2±0.4−3.3±0.6−3.7±0.80.120
  • Data are mean±SD.

  • ANOVA was used to determine significance among the three groups followed by Bonferroni statistical test for multiple comparisons.

  • Fat mass (kg) is total fat weight in whole body.

  • *P<0.05 vs most sensitive.

  • A:G, android to gynoid % fat ratio; ALT, alanine transaminase; ANOVA, analysis of variance; AST, aspartate aminotransferase; BMC, bone marrow concentration; BMI, body mass index; Cre, creatinine; DBP, diastolic blood pressure; ELF, enhanced liver fibrosis; FBG, fasting blood glucose; FH, family history; HA, hyaluronic acid; Hb, hemoglobin; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA2-IR, Homeostatic Model Assessment 2 for Insulin Resistance; HR, heart rate; LDL, low-density lipoprotein; M value, whole-body glucose disposal rate; NAFLD, non-alcoholic fatty liver disease; PIIINP, procollagen III amino-terminal peptide; SBP, systolic blood pressure; T chol, total cholesterol; T2D, type 2 diabetes; TG, triglycerides; TIMP-1, TIMP metallopeptidase inhibitor 1; TSH, thyroid stimulating hormone.